Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 0.000p
  • 52 Week Low: 0.000p
  • Currency: UK Pounds
  • Shares Issued: 374.35m
  • Volume: 0
  • RiskGrade: 435

Latest ShareCast News

ValiRx launches prostate cancer subsidiary Blue Ribbon Bio

By Josh White

Date: Tuesday 26 Aug 2025

(Sharecast News) - ValiRx announced a new wholly owned subsidiary Blue Ribbon Bio on Tuesday, to consolidate its prostate cancer assets and accelerate development of its Val201 peptide therapy.

Valirx ShareCast News

Ambrose exercises ValiRx oncology option worth u... 20-Jun-2025 ShareCast
ValiRx terminates exclusive negotiations with Th... 03-Apr-2025 ShareCast
ValiRx's Inaphaea inks deal with UK-based Screen... 03-Feb-2025 ShareCast
ValiRx enters evaluation and option deal with Ca... 29-Jan-2025 ShareCast
ValiRx further extends letter of intent with The... 31-Dec-2024 ShareCast

Valirx Regulatory News

Cytolytix Commercial update 01-Sep-2025 07:00 RNS
Commercial update 26-Aug-2025 07:00 RNS
ValiRx Awarded Grant from Open University 07-Aug-2025 10:51 RNS
Update on Evaluation Agreement with Stingray Bio 05-Aug-2025 09:53 RNS
Licensing Agreement with Dominion Biotech Ltd 04-Aug-2025 07:00 RNS

Valirx Newspaper Links

Business Digest 24-Sep-2006 Sunday Times

Valirx Tips & Analysis

IOS acquires Indian restaurants owner 30-Jan-2008 Times
Small caps 13-Nov-2007 Times
Kelda springs to life as takeover talk bubbles up 11-Sep-2007 Telegraph
Kelda climbs on revived takeover speculation 11-Sep-2007 The Independent
Alliance & Leicester buoyed by talk of NAB bid 09-Aug-2007 The Independent

Valirx News Wires

No recent information was found.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Valirx Market Data

Currency UK Pounds
Share Price 1.00p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 0.000p
52 Week Low 0.000p
Volume 0
Shares Issued 374.35m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
41.52% above the market average41.52% above the market average41.52% above the market average41.52% above the market average41.52% above the market average
46.34% above the sector average46.34% above the sector average46.34% above the sector average46.34% above the sector average46.34% above the sector average
Price Trend
87.83% below the market average87.83% below the market average87.83% below the market average87.83% below the market average87.83% below the market average
81.82% below the sector average81.82% below the sector average81.82% below the sector average81.82% below the sector average81.82% below the sector average
Income Not Available
Growth
26.62% above the market average26.62% above the market average26.62% above the market average26.62% above the market average26.62% above the market average
31.03% above the sector average31.03% above the sector average31.03% above the sector average31.03% above the sector average31.03% above the sector average

Valirx Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Valirx Key Personnel

CFO Gerald Desler

Top of Page